Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

Clinical trial NCT05826483 · UNKNOWN

Trial details

NCT number: NCT05826483
Sponsor: Guangzhou Institute of Respiratory Disease
Status: UNKNOWN
Phase: Phase 1
Study type: INTERVENTIONAL

Malignant Tumor of Lung Poor Performance Status

Start date: 2022-01-01
Primary completion: 2024-12-28
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.